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Abstract
Objective: We assessed trends in the proportion of transmitted (TDR) and acquired (ADR) HIV drug resistance and
associated mutations between 2001 and 2011 in the German ClinSurv-HIV Drug Resistance Study.
Method: The German ClinSurv-HIV Drug Resistance Study is a subset of the German ClinSurv-HIV Cohort. For the ClinSurv-
HIV Drug Resistance Study all available sequences isolated from patients in five study centres of the long term observational
ClinSurv-HIV Cohort were included. TDR was estimated using the first viral sequence of antiretroviral treatment (ART) naı̈ve
patients. One HIV sequence/patient/year of ART experienced patients was considered to estimate the proportion of ADR.
Trends in the proportion of HIV drug resistance were calculated by logistic regression.
Results: 9,528 patients were included into the analysis. HIV-sequences of antiretroviral naı̈ve and treatment experienced
patients were available from 34% (3,267/9,528) of patients. The proportion of TDR over time was stable at 10.4% (95% CI
9.1–11.8; p for trend = 0.6; 2001–2011). The proportion of ADR among all treated patients was 16%, whereas it was high
among those with available HIV genotypic resistance test (64%; 1,310/2,049 sequences; 95% CI 62–66) but declined
significantly over time (OR 0.8; 95% CI 0.77–0.83; p for trend,0.001; 2001–2011). Viral load monitoring subsequent to
resistance testing was performed in the majority of treated patients (96%) and most of them (67%) were treated
successfully.
Conclusions: The proportion of TDR was stable in this study population. ADR declined significantly over time. This decline
might have been influenced by broader resistance testing, resistance test guided therapy and the availability of more
therapeutic options and not by a decline in the proportion of TDR within the study population.
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Introduction
Since the introduction of combination antiretroviral therapy the
morbidity and mortality among people infected with HIV has
been reduced dramatically [1]. However, antiretroviral treatment
(ART) of HIV is still life-long, and the prolonged duration of
therapy with emerging HIV drug resistance might leave many
patients without treatment options. In recent years treatment
options improved due to the approval of second generation drugs
and new antiretroviral drug classes [2]. Moreover, fixed dose
combinations were approved, increasing the level of adherence
among patients [3], which also affects resistance development [4].
HIV drug resistance may be transmitted among recently infected
patients within transmission chains but may also be acquired
during non-suppressive antiretroviral treatment from ART expe-
rienced patients [5,6]. In Germany, according to current
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treatment guidelines all patients should be genotyped routinely
prior to ART initiation [7].
HIV drug resistance surveillance has been performed in many
Western European countries within different study populations
and settings. Most studies were performed in patients during
primary HIV infection or in patients chronically infected with
HIV prior to ART initiation [8–12]. Currently no epidemiological
resistance data base exists, and no central repository for viral
sequences is established in Germany. Studies on population level
including all HIV sequences produced in routine clinical settings
for estimating the proportion of TDR or ADR are not available.
Therefore the aim of this study was to estimate trends in the
proportion of overall TDR and ADR and within different drug
classes between 2001 and 2011, as well as single mutations within
the German ClinSurv-HIV Drug Resistance Study. This is the first
time that viral sequence data is linked with epidemiological and
antiretroviral treatment data in a large resistance study in
Germany including ART naı̈ve as well as treated patients in
order to estimate the proportion of transmitted and acquired HIV
drug resistance.
Materials and Methods
The ClinSurv-HIV Cohort, study design
The ClinSurv-HIV project protocol was approved by the
German Federal Commissioner for Data Protection. ClinSurv-
HIV is an ongoing, prospective, long-term observational cohort
study. The study design has been described in detail elsewhere
[13]. In brief, 15 clinical centres in different, predominantly urban
areas in Germany are involved in the study and consecutively
monitored subjects since January 1st 1999. The cohort comprises
all individuals infected with HIV in the participating clinical
centres. Only basic data are reported every six months. The data
set is anonymized and comprises demographic data, time-related
variables on clinical events, AIDS-defining diagnoses, and detailed
data on antiretroviral treatment. Patients with available sequences
were identified at the five ClinSurv-HIV Drug Resistance Study
centres participating in this analysis. Any identifying information
was removed at the local study centres, the sequences were
labelled with a new identifier allowing linkage with anonymized
patient data in the ClinSurv data base. All data analyses were
performed on the anonymized data set.
The Robert Koch Institute (RKI) is the German national public
health institute, therefore the Federal Commissioner for Data
Protection is the responsible entity for studies which are conducted
by the Robert Koch Institute. Information on HIV infection
collected in ClinSurv corresponds to the data reported to the RKI
according to legal requirements implemented by the national
Protection against Infection act (IfSG) of 2001. All patient data
collected in ClinSurv are generated during routine care. The
German Federal Commissioner for Data Protection therefore
waived the need for ethical approval for the ClinSurv study. No
written informed consent is required from patients.
ClinSurv-HIV Drug Resistance Study
For the ClinSurv-HIV Drug Resistance substudy, all patients
infected with HIV under care in five study sites (University of
Cologne, University of Düsseldorf, University of Hanover,
University of Munich, ICH Study Centre Hamburg) of the
ClinSurv-HIV Cohort study group with at least one HIV
genotypic resistance analysis result were identified. The nucleotide
sequences were processed through the Stanford University
Genotypic Resistance Interpretation Algorithm (www.hivdb.
stanford.edu; HIVdb version 6.2.0; 2012) in order to identify
amino acid substitutions and to determine drug susceptibility. For
epidemiological analysis, HIV sequences isolated from ART naı̈ve
patients were analysed using the surveillance HIV drug resistance
mutation list, SDRM [14]. Only the first HIV genotypic resistance
test per patient while treatment naı̈ve was considered for the
estimation of the prevalence of TDR. HIV sequences isolated from
ART experienced patients were analysed using the mutation list of
the International Antiviral Society-USA, IAS, 2011 [15]. Overall
ADR was estimated by including one HIV sequence/patient/year
from antiretroviral treatment experienced patients. For the
estimation of ADR within different drug classes only viral
sequences of patients treated with the respective drug class were
considered. HIV subtype on patient level was assigned based on
the first available viral sequence of a patient centrally using the
REGA HIV-1 Subtyping Tool - Version 2.0 [16].
Statistical analysis
Viral sequences available between 1998 and 2011 were
collected and analysed. For the estimation of trends in the
proportion of HIV drug resistance over time viral sequences
sampled between 2001 and 2011 were included into the analyses.
The characteristics of patients with available sequences compared
to those who were not genotyped were compared with simple
logistic regression. Patients and viral sequences were categorised
into ART naı̈ve and treatment experienced. Viral sequences were
considered to originate from treatment naı̈ve patients in case of
ART start #15 days prior to the date of resistance testing, to
account for delays in the documentation of the date of resistance
testing results and the actual date of blood sampling. The time
between resistance testing and antiretroviral treatment start and
the proportion of patients with resistance test before ART start
were analysed by using data from patients with documented first-
line treatment start. The proportion of patients with antiretroviral
treatment failure undergoing resistance testing was calculated for
patients with first line treatment start in one of the resistance study
centres who had .180 days of treatment experience and a
resistance test within 90 days after virologic failure. Virologic
failure was defined as two consecutive viral load measurements
with .50 copies/ml within 180 days or one viral load
measurement with .1000 copies/ml. For different drug classes
the proportion of cumulative ART exposure per year, the median
days of previous ART exposure and the proportion of patients
showing history of exposure to the respective drug class were
calculated, excluding treatment interruption time. A simple linear
regression was performed on the duration of antiretroviral
treatment exposure in days prior to resistance testing with
increasing year of genotyping for different drug classes and on
the total treatment exposure. In a univariate analysis of factors
associated with HIV drug resistance the following covariates were
separately included: age, gender, transmission group category,
HIV subtype, ART interruption, duration of previous ART
exposure, CD4 cell count, and plasma viral load at the time point
of testing or 30 days prior to or 15 days after testing, year of
resistance test at documented ART start. Factors significantly
associated with acquired HIV drug resistance in a univariate
analysis were included into multiple logistic regression. For the
analysis of factors associated with acquired HIV drug resistance
only the last sequence of ART experienced patients was included.
The proportion of patients showing a history of exposure to a drug
class, trends in the proportion of patients with ART interruption,
gender, transmission group category, HIV subtype were calculated
by simple logistic regression. Median plasma viral loads and CD4
cell counts were calculated for ART naı̈ve and treated patients.
The Mann-Whitney-U-test (MWT) was used to compare viral
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loads, CD4 cell counts and the age at ART start for patients with
resistant and susceptible HIV. Confidence intervals were calcu-
lated using a Wilson score confidence interval. Trends in the
prevalence of HIV drug resistance mutations, DRMs, (pfor trend)
were calculated by logistic regression. All p-values were two sided,
and a p-value of ,0.05 was considered significant. Data were
analysed using SPSS 18.0.3 and R 2.12.1.
Results
A total of 9,528 ClinSurv patients were enrolled in the five study
centers participating in the resistance study. 4,989 viral sequences
were collected from 34% (3,267/9,528) of these patients. Nearly
half of these HIV sequences (47%; 2,365/4,989) were generated
while patients were ART naı̈ve, the other half of viral sequences
(50%; 2,495/4,989) were produced while patients were treated
with antiretroviral drugs. The ART status of the patients could not
be clarified for 3% (129/4,989) of the HIV sequence data. Of the
patients who have not been genotyped (n = 6,261), 4,895 patients
were seen in the resistance study centres while ART naı̈ve, and of
5,262 patients data were collected while treated with antiretroviral
drugs (Table 1). In total 86% (8,165/9,528) of the patients in the
five Resistance Study centres were ART experienced. Among all
patients who have been treated, HIV drug resistance was
identified in 16% (1,347/8,165) of patients.
Characteristics of patients with available sequences
Patients were predominantly male (82%; 2,683/3,267); 18%
(584/3,267) were female. Median age at the time point of HIV
genotypic resistance testing was 40 years (33.0–47.0). Median CD4
cell count at first visit was 310 cells/ml (IQR: 147–490). The main
transmission group category was sex between men (58%; 1,904/
3,267), followed by heterosexual contacts (14%; 445/3,267) and by
patients originating from high-prevalence countries (12%; 405/
3,267). Median time between first HIV genotypic resistance test
and ART start was 33 days (IQR: 13–169). The proportion of
patients with resistance test before ART start in the five study
centres increased from 0.4% in 2000 to 69% in 2009 and declined
thereafter to 46% in 2010 and 21% in 2011. The duration
between HIV diagnosis and first resistance test was in median 45
days (IQR: 16–481) for ART naı̈ve patients.
The characteristics of patients with resistance test and those
without differed as follows: within the category risk of transmission
in the Resistance study group we observed more patients with
heterosexual contacts (with resistance test: 13.6% vs. 11.6%
without test, p = 0.04), more patients from high prevalence
countries (with resistance test: 12.4% vs. 10.5% without test,
p = 0.03) and fewer patients with intravenous drug use (with
resistance test: 5.5% vs. 8.8% without test, p,0.001); within the
category region of origin in the Resistance study group we
observed more patients being from Africa, Near East (with
resistance test: 11.6% vs. 9.1% without test) (Table 1). Patients
were predominantly infected with HIV-1 subtype B strains (69%;
2,240/3,267), but 18% (604/3,267) of patients harbored a non-B
subtype infection. For 13% (423/3,267) of patients the HIV-1
subtype could not be determined by REGA HIV-1 Subtyping
Tool. HIV-1 subtype A was most prevalent among the non-B
subtypes (9%), followed by circulating recombinant forms (4%)
(Table 1). The majority of women were infected with HIV-1 non-
B subtypes (non-B subtypes: 53%; 312/584 vs. subtype-B: 33%;
192/584), predominantly subtype A (24%; 140/584). Nearly half
of the female study population originated from high-prevalence
countries: 46% (270/584). At time point of HIV genotypic
resistance testing, the median viral load (VL) for ART naı̈ve
patients was 4.73 log10 copies/ml (IQR: 4.1–5.3), median CD4 cell
count was 285 cells/ml (IQR: 151–437). Both VL and CD4 cell
counts did not differ significantly between patients infected with
susceptible or resistant viruses (VL susceptible: 4.74, IQR: 4.1–5.3
vs. VL resistant: 4.69, IQR: 4.2–5.3, p = 0.93; CD4 susceptible:
286, IQR: 150–437 vs. CD4 resistant: 274, IQR: 169–443,
p = 0.90). The median VL of treated patients with detectable
plasma virus was 4.02 log10 copies/ml (IQR: 3.1–4.8), median
CD4 cell count of treated patients was 271 cells/ml (IQR: 150–
423). VL and CD4 cell count did not differ significantly between
patients infected with susceptible or resistant viruses (VL
susceptible: 4.13, IQR: 2.8–4.9 vs. VL resistant: 3.96, IQR: 3.2–
4.7, p = 0.50; CD4 susceptible: 280, IQR: 160–430 vs. CD4
resistant: 266, IQR: 145–420, p = 0.29).
Transmitted HIV drug resistance, TDR
Overall TDR according to SDRM list was identified among the
first HIV sequences available before ART initiation in 10.4%
(203/1,950; 95% CI 9.1–11.8) and remained stable over time
(OR: 0.98; p for trend = 0.6; 2001–2011) (Figure 1A). Nucleoside
reverse transcriptase inhibitor (NRTI) resistance was detected in
7% (128/1,950; 95% CI 6–8), followed by 3% (61/1,950; 95% CI
2–4) non-nucleoside reverse transcriptase inhibitor (NNRTI)
resistance and 3% (56/1,950; 95% CI 2–4) protease inhibitor
(PI) resistance. The prevalence of thymidine analogue mutations
(TAMs) was 5% (89/1,950; 95% CI 4–6), and revertant mutations
at position 215 of the reverse transcriptase (RT) were found in 3%
(56/1,950; 95% CI 2–4) of first viral strains analysed from ART
naı̈ve patients (Table 2).
Acquired HIV drug resistance, ADR
ADR was calculated using maximal one HIV sequence per year
of antiretroviral treatment experienced patients. Overall ADR was
high (64%; 1,310/2,049 sequences; 95% CI 62–66) but declined
significantly over time (OR 0.8; 95% CI 0.77–0.83; pfor trend,
0.001; 2001–2011) (Figure 1B). To estimate HIV drug resistance
in different drug classes, only viral sequences isolated from those
patients who received the respective drug class were included into
the analysis. Predominantly NNRTI resistance was identified
(55%; 730/1333; 95% CI 52–57), followed by NRTI resistance in
51% (1,007/1,958; 95% CI 49–54) and PI resistance in 30% (473/
1586; 95% CI 28–32). The proportion of ADR declined
significantly over time for all three drug classes (pfor trend,0.001;
2001–2011) (Figure 1C). INI resistance was detected in 30% (10/
33; 95% CI 17–47) of INI treated patients corresponding to 7%
(10/150; 95% CI 4–12) among all HIV integrase sequences of
ART experienced patients (Table 2). The most prevalent NRTI
associated mutation identified among ART experienced patients
was M184IV (34%). The most common TAMs were T215FY
(25%), M41L (21%) and D67N (18%). The prevalence of PI
mutations I84V and I54LM associated with darunavir and
atazanavir resistance were 8% and 5%, respectively. The PI
associated resistance mutations M46L and L90M were most
prevalent with 14% (Figure 2).
Factors associated with acquired HIV drug resistance
Factors significantly associated with a lower risk of ADR by
using a univariate model were being female compared to male,
transmission group category IDU compared to MSM, being
infected with non-B subtype compared to subtype B, reported
ART interruption at genotyping compared to reported continuous
antiretroviral treatment at the time of genotyping and the
cumulative duration of ART interruption (Table 3). In a multiple
logistic regression significant factors from the univariate analysis
Trends in HIV Drug Resistance in Germany
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Figure 1. Proportion of HIV drug resistance in sequences from treatment naı̈ve patients and treatment experienced patients
between 2001 and 2011. A Proportion of HIV drug resistance was determined using the first Prot/RT sequences from treatment naı̈ve patients
(n = 1950) by year according to the SDRM mutation list (Bennett et al. 2009). The proportion of TDR over time was stable at 10.4% (95% CI 9.1–11.8; p
Trends in HIV Drug Resistance in Germany
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were included into the model. Factors significantly associated with
a lower risk of ADR were being female compared to male,
reported ART interruption compared to reported continuous
antiretroviral treatment at the time of genotyping, increasing
calendar year of genotyping and the cumulative duration of ART
interruption (Table 4). The duration of antiretroviral treatment
was associated with a higher risk of ADR in both the univariate
and multiple logistic regression.
To investigate the reduced risk for women to carry resistant
viral strains, the duration of previous ART exposure was analysed.
Results showed, that women had a significantly lower ART
exposure time than men (women median 3.9 years, IQR 0.8–7.1
to men median 5.0, IQR 1.3–9.1, respectively; OR 0.95, 95%CI
0.92–0.98, p,0.001).
Treatment exposure
The majority of antiretroviral treated patients (98%; 1,956/
1,987) showed a history of exposure to NRTIs, 67% (1,333/1,987)
to NNRTIs, 80% (1,584/1,987) to PIs and 5% (103/1,987) to
INIs.
Over time there was a small but significant decrease in the
proportion of patients with exposure to NRTI (from 100% in 2001
for trend = 0.6; 2001–2011). B Proportion of overall ADR (64%; 1,310/2,049 sequences; 95% CI 62–66) declined significantly over time (OR 0.8; 95% CI
0.77–0.83; p for trend,0.001; 2001–2011) in sequences from treated patients (n = 2,049) according to IAS mutation list 2011. C Proportion of ADR
within different antiretroviral drug classes declined for all classes (NNRTI 55%, NRTI 51%, PI 30%; p for trend,0.001; 2001–2011) in sequences from
patients treated with the respective drug class according to IAS mutation list 2011.
doi:10.1371/journal.pone.0104474.g001
Table 2. Prevalence of transmitted HIV drug resistance according to the SDRM mutation list and of acquired HIV drug resistance
according to the IAS mutation list.
Transmitted HIV drug resistance n (%) (95% CI) Beta OR (95% CI) p for trend
First Prot/RT sequence from naive patients Prevalence of DRMs according to SDRM mutation list (Bennett D. et al. 2009)
Total 1950 (100.0%) p (2001–2011)
DRMs 203 (10.4%) (9.1–11.8) 20.018 0.98 (0.92–1.04) 0.561
NRTI mutations 128 (6.6%) (5.5–7.8) 20.016 0.98 (0.91–1.06) 0.667
TA mutations 89 (4.6%) (3.7–5.6) 0.002 1.00 (0.92–1.10) 0.972
T215revertants 56 (2.9%) (2.2–3.7) 0.058 1.06 (0.94–1.19) 0.337
NNRTI resistance 61 (3.1%) (2.4–4.0) 20.031 0.97 (0.87–1.08) 0.560
PI resistance 56 (2.9%) (2.2–3.7) 20.020 0.98 (0.88–1.10) 0.723
Single/multi drug class resistance 203 (10.4%)
One class resistance 169 (8.7%) (7.5–10.0)
Two classes resistance 26 (1.3%) (0.9–1.9)
Three classes resistance 8 (0.4%) (0.2–0.8)
Acquired HIV drug resistance n (%) (95% CI) Beta OR (95% CI) p for trend
Prot/RT sequences from treated patients Prevalence of DRMs according to IAS list (Johnson V. et al. 2011)
Total 2049 (100.0%) p (2001–2011)
DRMs 1310 (63.9%) (61.8–66.0) 20.220 0.80 (0.77–0.83) ,0.001
Subgroup of NRTI treated patients 1958 (100.0%)
NRTI mutations 1007 (51.4%) (49.2–53.6) 20.224 0.80 (0.77–0.83) ,0.001
TA mutations 696 (35.5%) (33.5–37.7) 20.216 0.81 (0.78–0.84) ,0.001
T215revertants 72 (3.7%) (2.9–4.6) 0.001 1.00 (0.92–1.09) 0.990
Subgroup of NNRTI treated patients 1333 (100.0%)
NNRTI resistance 730 (54.8%) (52.1–57.4) 20.144 0.87 (0.83–0.90) ,0.001
Subgroup of PI treated patients 1586 (100.0%)
PI resistance 473 (29.8%) (27.6–32.1) 20.227 0.80 (0.76–0.83) ,0.001
Single/multi drug class resistance 1310 (63.9%)
One class resistance 490 (23.9%) (22.1–25.8)
Two classes resistance 500 (24.4%) (22.6–26.3)
Three classes resistance 320 (15.6%) (14.1–17.3)
Integrase sequences from treated patients 150 (100.0%) p (2006–2011)
INI resistance 10 (6.7%) (3.7–11.8)
INI resistance on INI treated (n = 33) 10 (30.3%) (17.4–47.3) 20.571 0.57 (0.30–1.06) 0.077
Highly significant results are marked in bold fonts.
doi:10.1371/journal.pone.0104474.t002
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Figure 2. Proportion of resistance mutations in sequences from treatment naı̈ve and treatment experienced patients identified
between 2001 and 2011. A Proportion of resistance mutations in first Prot/RT sequence from treatment naı̈ve patients (n = 1950; mutations with
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to 98% in 2011; OR 0.78; 95% CI 0.67–0.91; p = 0.002), NNRTI
use remained stable during the period of observation (from 65% in
2001, peaking in 2007 at 76% and leveling off thereafter with 63%
in 2011; OR 1.0; 95% CI 0.96–1.0; p = 0.92). PI exposure
increased significantly over time (from 80% in 2001 to 90% in
2011; OR 1.1; 95% CI 1.0–1.1; p = 0.009). INI use increased
significantly over time (from 3% in 2007 to 25% in 2011; OR 2.0;
95% CI 1.7–2.3; p,0.001).
The simple linear regression showed a non-significant slight
increase in the duration of ART exposure in days prior to
resistance testing with increasing year of genotyping for NRTI (R2:
0.00; coefficient B: 6.6; 95% CI 219–32; p = 0.62), a significant
increase for NNRTI (R2: 0.007; coefficient B: 26.6; 95% CI 13–
40; p,0.001), for PI (R2: 0.006; coefficient B: 35.8; 95% CI 16–
55; p,0.001) and for INI (R2: 0.045; coefficient B: 8.6; 95% CI 7–
10; p,0.001). The duration of total ART exposure prior to
resistance testing increased but not significantly over time (R2:
0.001; coefficient B: 22.8; 95% CI 23.3–49; p = 0.087).
Considering the regimen at resistance testing there was an
increase in boosted PI containing regimens, especially for ritonavir
boosted NRTI/PI combinations (from 10% in 2001 to 46% in
2011, NRTI+PI, overall 35%). PI regimens without booster almost
disappeared over time. Triple class combinations like NRTI/
NNRTI/PI declined over time whereas newer drug class
containing regimens increased (from 0.6% in 2002 to 21% in
2011, overall 7%). Combination of NRTI/NNRTI showed a
decline over time (from 29% in 2001 to 20% in 2010 and only
10% in 2011, overall 20%). Treatment interruption at the time of
resistance testing was highly frequent in this study population but
remained stable over time (17% in 2002 to 17% in 2011, overall
20%; OR 1.04; 95% CI 1.0–1.1; p for trend = 0.073; 2002–2011).
$0.3% shown) according to SDRM mutation list (Bennett 2009 et al.). B Proportion of resistance mutations in sequences from treated patients (Prot/
RT n = 2,049; Int n = 150) according to IAS mutation list 2011. Bars in black: NRTI mutations, grey bars: TAMS, white bars: NNRTI mutations, bars in light
grey: PI mutations, dark grey bars: INI mutations.
doi:10.1371/journal.pone.0104474.g002
Table 3. Univariate analysis of factors associated with HIV drug resistance (IAS list 2011) among ART experienced patients (last
sequence).
Total resistant HIV susceptible HIV OR (95% CI) p-Value
Treatment experienced patients, n (%) 1437 (100%) 857 (59.6%) 580 (40.4%)
Median age at ART start, years (IQR) 36.2 (30.1–43.4) 35.8 (30.4–43.3) 36.4 (29.7–43.6) 0.630a
Sex, n (%)
Men 1143 (79.5%) 709 (82.7%) 434 (74.8%) 1
Women 294 (20.5%) 148 (17.3%) 146 (25.2%) 0.62 (0.48–0.80) ,0.001b
Mode of HIV transmission, n (%)
Men who have sex with men 784 (54.6%) 483 (56.4%) 301 (51.9%) 1
High prevalence country 210 (14.6%) 117 (13.7%) 93 (16.0%) 0.78 (0.58–1.07) 0.121b
Heterosexuals 180 (12.5%) 114 (13.3%) 66 (11.4%) 1.08 (0.77–1.51) 0.667b
Intravenous drug use 111 (7.7%) 56 (6.5%) 55 (9.5%) 0.64 (0.43–0.95) 0.025b
Others 21 (1.5%) 14 (1.6%) 7 (1.2%) 1.25 (0.50–3.12) 0.638b
Unknown 131 (9.1%) 73 (8.5%) 58 (10.0%) 0.78 (0.54–1.14) 0.203b
HIV subtype, n (%)
Subtype B 1007 (70.1%) 637 (74.3%) 370 (63.8%) 1
Subtype non-B 263 (18.3%) 133 (15.5%) 130 (22.4%) 0.59 (0.45–0.78) ,0.001b
Not typeable 167 (11.6%) 87 (10.2%) 80 (13.8%) 0.63 (0.45–0.88) 0.006b
Treatment status at genotyping, n (%)
Under treatment 1091 (75.9%) 726 (84.7%) 365 (62.9%) 1
Pause 293 (20.4%) 102 (11.9%) 191 (32.9%) 0.27 (0.21–0.35) ,0.001b
Missing 53 (3.7%) 29 (3.4%) 24 (4.1%) 0.61 (0.35–1.06) 0.079b
Treatment exposure time, per year 1.13 (1.11–1.17) ,0.001b
Duration of interruption, per year 0.84 (0.79–0.89) ,0.001b
Viral load at genotyping, n (%) 1151 (80.1%) 688 (80.3%) 463 (79.8%)
Median HIV-RNA log10 cps/ml (IQR) 3.94 (2.98–4.76) 3.87 (3.09–4.61) 4.11 (2.80–4.88) 0.181a
CD4 cells at genotyping, n (%) 1097 (76.3%) 659 (76.9%) 438 (75.5%)
Median CD4 cells/ml (IQR) 280 (164–434) 278 (161–435) 286 (166–430) 0.721a
IQR: interquartile ranges;
CI: 95% confidence intervals;
aMann-Whitney-U-Test;
bsimple logistic regression;
Highly significant results are marked in bold fonts;
doi:10.1371/journal.pone.0104474.t003
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The proportion of patients undergoing resistance testing within
90 days after failing ART in the five study centres increased from
2.2% in 2001 to 21% in 2010 and amounted to 13% in 2011.
Treatment success post resistance testing was observed for 67%
(928/1,386) of ART experienced patients. HIV drug resistance
was observed in 60% (828/1,386) of this study population whereas
40% (558/1,386) showed no resistance associated mutations.
However, the proportion of patients with successful viral
suppression after resistance testing did not differ between those
patients with susceptible and resistant HIV strains (67%; 553/828
resistant HIV vs. 67%; 375/558 susceptible HIV). A switch of
therapy between different drug classes was observed significantly
more frequent for patients harbouring resistant strains (64%; 530/
828) than for patients with susceptible viruses (50%; 279/558).
Discussion
Results of this study showed that the estimated prevalence of
TDR over time among ART naı̈ve patients remained stable at a
high level, whereas overall prevalence of ADR as well as drug
resistance within different drug classes in patients under antiret-
roviral treatment declined significantly over time. The decline of
ADR could be influenced by several factors. Presumably
antiretroviral drug related effects like enhanced treatment
optimization and resistance test guided therapy as well as broader
resistance testing in the study population are considered to be
reasonable factors influencing this decline.
The high but stable level of TDR is comparable to other
prevalence estimates in long term observational cohorts in
Germany as well as in other European countries [8,17,18] and
to cohorts with patients chronically infected with HIV in other
Western European countries [17–19]. Since the date of HIV
infection is not known in this study population, the estimates of
TDR might be underestimates as in many cases reversion to wild
type virus might have occurred. However, the proportion of TDR
observed in antiretroviral treatment naı̈ve patients (10.4%) was
comparable to those observed in German HIV-1 seroconverters
(12%) [8,12]. The proportion of TDR in previously untreated
patients reflects transmission of resistant strains at the time-point of
infection mostly some years ago with the risk that primary
transmitted mutations at the time of resistance testing are not
visible anymore. This requires regular monitoring and evaluation
of TDR. The most frequent mutations observed in ART naı̈ve
patients were T215 revertants which were transmitted as revertant
or evolved from viruses harbouring a T215F or T215Y mutation.
As also reported by studies from other countries [20] TAMs were
the predominant single mutations determined in this study
population despite changing prescription policies regarding
stavudine and zidovudine, which select for these mutations. One
possible explanation for this phenomenon might be that frequently
used drugs like abacavir and tenofovir maintain the prevalence of
such mutations in patients receiving antiretroviral therapy, and
mutations may be transmitted in case of insufficient virus
suppression [21,22]. In contrast, the proportion of ADR in
antiretroviral treatment experienced patients at the time point of
resistance testing declined significantly over the period of
observation in this study population, as also observed in other
Western European study populations [23]. This decline was not
related to a lower proportion of TDR in treatment naı̈ve patients.
The proportion of ADR among the treated population could be
influenced by the time of drug exposure to different drug classes,
the number of substances ever used, and the time of ART
interruption. The risk of ADR was significantly lower in patients
with documented ART interruption at the time of genotyping than
in those patients with continuous treatment as showed by the
univariate and multivariate analysis of factors associated with the
risk of ADR. The reason might be that in the absence of selective
drug pressure, secondary resistant mutations are rapidly over-
grown by wild type virus [24]. Although studies of ART
interruption have demonstrated the potential for negative clinical
consequences like increased risk of death and serious AIDS
defining events [25], non-structured ART interruptions are
common in daily clinical routine and the proportion of patients
who interrupted therapy remained stable over time at a high level
(21%) as shown in this study.
As expected the time a patient was exposed to ART prior to
resistance testing was significantly associated with a higher risk of
ADR in the univariate and multivariate analysis. The significantly
lower risk of ADR for women was most likely caused by their
significantly shorter duration of ART exposure prior genotyping.
Regarding the duration of ART exposure prior to resistance
testing there was a significant increase in treatment exposure for
NNRTIs, PIs and INIs whereas NRTI exposure and the complete
duration of treatment exposure increased without a level of
Table 4. Multiple regression analysis of factors associated with HIV drug resistance (IAS list 2011) among ART experienced patients
(last sequence).
Total resistant HIV susceptible HIV OR (95% CI) p-Value
Treatment experienced patients, n (%) 1437 (100%) 857 (59.6%) 580 (40.4%)
Sex, n (%)
Men 1143 (79.5%) 709 (82.7%) 434 (74.8%) 1
Women 294 (20.5%) 148 (17.3%) 146 (25.2%) 0.71 (0.53–0.94) 0.017
Treatment status at genotyping, n (%)
Under treatment 1091 (75.9%) 726 (84.7%) 365 (62.9%) 1
Pause 293 (20.4%) 102 (11.9%) 191 (32.9%) 0.32 (0.24–0.42) ,0.001
Missing 53 (3.7%) 29 (3.4%) 24 (4.1%) 0.61 (0.34–1.10) 0.102
Calendar year of resistance test (2001–
2011)
0.80 (0.76–0.84) ,0.001
Treatment exposure time, per year 1.13 (1.10–1.16) ,0.001
Treatment exposure time is the accumulated time documented for a patient to receive antiretroviral therapy, excluding times of interruption.
doi:10.1371/journal.pone.0104474.t004
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significance. Therefore the highly significant decline in ADR
observed among treated patients with available resistance test was
not influenced by a declining duration of previous ART exposure
or by increasing ART interruptions over time in the study
population. In this study population PI exposure increased
significantly over time. In contrast, PI associated HIV drug
resistance in treated patients declined significantly. The enhanced
use of PI containing regimens and the increasing variety of second
generation PIs with higher resistance barriers might influence this
phenomenon [26]. Although the proportion of ADR was high in
treated patients, the majority of patients showed viral load
measurements under the detection limit subsequent to the last
resistance test. In view of the preventive effect of ART, these
subjects are unlikely to contribute substantially to onward
transmission of resistant HIV strains. The proportion of patients
who were successfully treated did not differ between those with
resistant HIV and those with susceptible viral strains, reflecting a
sufficient number of antiretroviral treatment options and a high
expertise in tailored individual treatment of HIV and careful
monitoring of antiretroviral treatment for the majority of patients
with ADR in this study. Since the introduction of the remuner-
ation of HIV resistance testing by statutory health insurances in
Germany in 2005, more and more patients were tested in clinical
routine assuming that this have influenced the decline of ADR in
the treated study population [7]. A significant increase in the
proportion of patients who were resistance tested before ART
initiation as well as in case of treatment failure was observed in this
study population. However, the figures are still lower than
expected if all patients are tested before ART start or in case of
treatment failure as recommended in the guidelines. The
proportion of patients tested before ART over calendar year as
well as the proportion of patients failing therapy undergoing
resistance testing may influence the proportion of observed HIV
drug resistance in a study population. Perhaps the selection among
persons before ART start, where we observe a rather consistent
trend of TDR, was not as large as among treated patients. It is
conceivable that there was a stronger selection bias to test patients
with more problematic courses of therapy and thus towards cases
with higher probability of HIV drug resistance in the initial years
before statutory introduction of resistance testing in 2005.
Currently only HIV resistance data from long term observa-
tional studies in different study populations before ART initiation
is available in Germany [8,9,19]. Therefore the ClinSurv- HIV
Drug Resistance Study attempted to link HIV viral sequence data
with epidemiological and treatment data to describe daily clinical
resistance testing practices and the proportion of HIV drug
resistance for both ART naı̈ve patients as well as for treatment
experienced patients in a subset of a large cohort study of people
infected with HIV in Germany.
Limitations
This study has some limitations. First, it is a convenience sample
of data collected from 5 urban sites of Germany. Therefore, the
study is only able to describe the situation based on the
information that has been provided by those study centers, and
did not reflect the overall situation for Germany. Furthermore, the
data was collected over time periods where resistance testing
became more widely used in routine clinical care. As we see the
majority of the tests were performed after statutory introduction of
resistance testing in 2005. Since the proportion of patients tested is
correlated with the proportion of observed cases this is important
to keep in mind in view of the findings. In addition, certain
information is not retrieved, such as the reasons why, despite
indication, no test was performed or the reasons for resistance
testing, e.g. in view of future treatment options after interruption
or due to an actual treatment failure. Evidence exists that in the
participating centers more HIV drug resistance tests were
performed than we observed by recording the data. It might be
that resistance tests were carried out in other laboratories that we
have not reached.
However, this report is the first description of HIV drug
resistance for both ART naı̈ve and treatment experienced persons
infected with HIV in Germany. With all constraints, it is
nevertheless one of the most comprehensive reports currently
available and gives insight into clinical resistance testing practices
and prevalence of HIV drug resistance of people infected with
HIV in Germany.
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‘‘Chantal Biya’’.
Trends in HIV Drug Resistance in Germany
PLOS ONE | www.plosone.org 11 August 2014 | Volume 9 | Issue 8 | e104474
Author Contributions
Conceived and designed the experiments: BB C. Kollan OH DS.
Performed the experiments: DS C. Kollan BB. Analyzed the data: DS
C. Kollan. Contributed reagents/materials/analysis tools: GF ES HJS CN
BJ MS JRB JE KM C. Kücherer. Wrote the paper: BB DS.
References
1. Palella Jr FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, et al. (1998)
Declining morbidity and mortality among patients with advanced human
immunodeficiency virus infection. New Engl J Med 338: 853–860.
2. Jones J, Taylor B, Wilkin TJ, Hammer SM (2007) Advances in antiretroviral
therapy. Top HIV Med 15: 48–82.
3. Kauf TL, Davis KL, Earnshaw SR, Davis EA (2012) Spillover adherence effects
of fixed-dose combination HIV therapy. Patient Prefer Adherence 6: 155.
4. Llibre JM, Arribas JR, Domingo P, Gatell JM, Lozano F, et al. (2011) Clinical
implications of fixed-dose coformulations of antiretrovirals on the outcome of
HIV-1 therapy. Aids 25: 1683–1690.
5. Brenner BG, Roger M, Moisi DD, Oliveira M, Hardy I, et al. (2008)
Transmission networks of drug resistance acquired in primary/early stage HIV
infection. Aids 22: 2509–2515.
6. de Mendoza C, Garrido C, Corral A, Ramirez-Olivencia G, Jimenez-Nacher I,
et al. (2007) Changing rates and patterns of drug resistance mutations in
antiretroviral-experienced HIV-infected patients. AIDS Res Hum Retroviruses
23: 879–885.
7. BUB-Richtlinien/Anlage A (2004) Genotypische Resistenztestung. Bundesan-
zeiger Nr. 57 (S. 5679).
8. Bartmeyer B, Kuecherer C, Houareau C, Werning J, Keeren K, et al. (2010)
Prevalence of Transmitted Drug Resistance and Impact of Transmitted
Resistance on Treatment Success in the German HIV-1 Seroconverter Cohort.
PLoS ONE 5: e12718.
9. Oette M, Kaiser R, Daumer M, Fatkenheuer G, Rockstroh JK, et al. (2007)
Epidemiology of primary drug resistance in chronically HIV-infected patients in
Nordrhein-Westfalen, Germany, 2001–2005. Dtsch Med Wochenschr 132: 977–
982.
10. Descamps D, Chaix ML, Andre P, Brodard V, Cottalorda J, et al. (2005) French
national sentinel survey of antiretroviral drug resistance in patients with HIV-1
primary infection and in antiretroviral-naive chronically infected patients in
2001–2002. J Acquir Immune Defic Syndr 38: 545–552.
11. Costagliola D, Descamps D, Assoumou L, Morand-Joubert L, Marcelin AG, et
al. (2007) Prevalence of HIV-1 drug resistance in treated patients: a French
nationwide study. J Acquir Immune Defic Syndr 46: 12–18.
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